Jeffrey Freedman, Executive Vice President at Evolution Health Group, joins Disruption/Interruption to reveal how AI and machine learning are revolutionizing pharmaceutical marketing. For decades, the pharmaceutical industry has been "data rich but insights poor," drowning in information while struggling to connect doctors, patients, and meaningful medical education. Freedman's personal healthcare experiences with his family drove him from Wall Street to pharma, where he now builds platforms that help pharmaceutical companies identify key opinion leaders, cut through the noise, and deliver life-saving information more efficiently. In this candid conversation, he demystifies the pharmaceutical industry, explains why the shift from direct-to-consumer to direct-to-physician marketing matters, and shares how his team is using technology to get treatments to patients faster while reducing costs.

Four Key Takeaways:

1. The Pharma Data Problem (9:04) - The pharmaceutical and medical industry is "data rich, but insights poor." Until recently, without AI and machine learning, massive amounts of data were simply growing without being properly analyzed. The ability to extract actionable insights has now shrunk dramatically, transforming how pharma companies can respond to patient needs.
2. Creating a Single Source of Truth (14:50) - Pharmaceutical companies have historically operated on disconnected spreadsheets across different regions and employees, causing critical information loss. Evolution Health Group's SaaS platforms aggregate data into a single source of truth, ensuring insights aren't lost when employees leave and enabling global coordination.
3. From Direct-to-Consumer to Direct-to-Physician (23:53) - Freedman advocates for lowering pharma's reliance on direct-to-consumer advertising and instead focusing budgets on educating physicians. Rather than patients self-prescribing based on commercials, doctors should be equipped with comprehensive education to prescribe the right treatments for the right patients, improving outcomes and reducing confusion.
4. Accelerating the Bench-to-Bedside Pipeline (29:46) - Through AI-powered insights and streamlined communication, the goal is to move products from the research bench to patients faster and more cost-effectively. This technology is already enabling treatments for rare diseases that were previously too expensive to develop, demonstrating how innovation can expand access to care.

Quote of the Show (23:48):
"Pharma is not this big scary monster that's put out there in the media. It's a bunch of people that really care.” – Jeffrey Freedman

Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome.

Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval

Ways to connect with Jeffrey Freedman:

LinkedIn: https://www.linkedin.com/in/jfreedman/
Company Website: https://evolutionhealthgroup.com

How to get more Disruption/Interruption: 

Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption

Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755

Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlD